Actavis to Buy Forest Laboratories for $25 Billion #gea #pharma #systems

Posted On Jun 13 2017 by

#forest pharma # Actavis to Buy Forest Laboratories for $25 Billion Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs. The deal is a win for billionaire investor Carl Icahn, Forest’s second-largest holder who gained seats on the company’s board in 2012 and 2013, and pushed for a sale. Forest investors will get cash and stock valued at $89.48 a share, based on the Feb. 14 closing price, the companies said today in a statement. The …


Dublin-based Actavis to buy Forest Labs for $25 billion #ajanta #pharma #limited

Posted On May 29 2017 by

#forest pharma # Dublin-based Actavis to buy Forest Labs for $25 billion Actavis. the world’s second-largest generic-drug maker by market value, is to buy Forest Laboratories in a cash and stock deal valued at about $25 billion. Actavis will pay the equivalent of $89.48 per share, representing a premium of 25 per cent to Forest’s Friday close. The offer comprises $26.04 in cash and 0.3306 Actavis shares for every Forest share. Forest had a market value of $19.3 billion at the close of trading last Friday. Dublin-headquartered Actavis was the most active buyer of drug companies over the past three …


Big Pharma Pockets $711 Billion in Profits by Price-Gouging Taxpayers and Seniors #elan #pharma

Posted On May 19 2017 by

#how big is the pharmaceutical industry # Big Pharma Pockets $711 Billion in Profits by Price-Gouging Taxpayers and Seniors Washington, DC – The 11 largest drug companies took $711.4 billion in profits over the 10 years ending in 2012, according to an analysis of corporate filings by Health Care for America Now (HCAN). The global pharmaceutical industry derived much of that profit from price-gouging the Medicare Part D prescription drug program for seniors and people with disabilities. Americans pay significantly more than any other country for the exact same drugs. In 2012 alone, the drug companies’ profits reached $83.9 billion, …


Drug company R – D: Nowhere near $1 billion #pharma #rep #jobs

Posted On May 16 2017 by

#drug research companies # Drug company R D argument for half a century, but the specific source of the $1 billion claim is a 2003 study published in the Journal of Health Economics by economists Joseph DiMasi of Tufts, Ronald W. Hansen of the University of Rochester, and Henry Grabowski of Duke. I will henceforth refer to this team as the Tufts Center group, because they were working out of the (drug-company-funded ) Tufts Center for the Study of Drug Development. The Tufts Center group “obtained from a survey of 10 pharmaceutical firms” the research and development costs of 68 …


Big Pharma Pockets $711 Billion in Profits by Price-Gouging Taxpayers and Seniors #pharmaceutical #firms

Posted On May 3 2017 by

#how big is the pharmaceutical industry # Big Pharma Pockets $711 Billion in Profits by Price-Gouging Taxpayers and Seniors Washington, DC – The 11 largest drug companies took $711.4 billion in profits over the 10 years ending in 2012, according to an analysis of corporate filings by Health Care for America Now (HCAN). The global pharmaceutical industry derived much of that profit from price-gouging the Medicare Part D prescription drug program for seniors and people with disabilities. Americans pay significantly more than any other country for the exact same drugs. In 2012 alone, the drug companies’ profits reached $83.9 billion, …


Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout #enobia #pharma

Posted On Apr 26 2017 by

#onyx pharma # Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout SOUTH SAN FRANCISCO, Calif. ( TheStreet ) — Every biotech CEO wants to say they bought an asset for X and sold it for 10X, yet few top executives manage to create value on this mammoth scale. Onyx Pharmaceuticals’ ( ONXX ) CEO Tony Coles just did it. The 10X is Amgen ( AMGN ) paying $10 billion in cash ($125 per share) to acquire Onyx. The deal, much discussed and analyzed since June, was finally announced Sunday night. But Amgen wouldn’t be buying Onyx …


Drug company R – D: Nowhere near $1 billion #taro #pharma

Posted On Apr 21 2017 by

#drug research companies # Drug company R D argument for half a century, but the specific source of the $1 billion claim is a 2003 study published in the Journal of Health Economics by economists Joseph DiMasi of Tufts, Ronald W. Hansen of the University of Rochester, and Henry Grabowski of Duke. I will henceforth refer to this team as the Tufts Center group, because they were working out of the (drug-company-funded ) Tufts Center for the Study of Drug Development. The Tufts Center group “obtained from a survey of 10 pharmaceutical firms” the research and development costs of 68 …


Actavis to Buy Forest Laboratories for $25 Billion #pharma #rep

Posted On Apr 19 2017 by

#forest pharma # Actavis to Buy Forest Laboratories for $25 Billion Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs. The deal is a win for billionaire investor Carl Icahn, Forest’s second-largest holder who gained seats on the company’s board in 2012 and 2013, and pushed for a sale. Forest investors will get cash and stock valued at $89.48 a share, based on the Feb. 14 closing price, the companies said today in a statement. The …


Dublin-based Actavis to buy Forest Labs for $25 billion #top #biopharma #companies

Posted On Apr 19 2017 by

#forest pharma # Dublin-based Actavis to buy Forest Labs for $25 billion Actavis. the world’s second-largest generic-drug maker by market value, is to buy Forest Laboratories in a cash and stock deal valued at about $25 billion. Actavis will pay the equivalent of $89.48 per share, representing a premium of 25 per cent to Forest’s Friday close. The offer comprises $26.04 in cash and 0.3306 Actavis shares for every Forest share. Forest had a market value of $19.3 billion at the close of trading last Friday. Dublin-headquartered Actavis was the most active buyer of drug companies over the past three …


Teva Buys Drug Rival, Barr, for $ Billion #pharma #industry #trends

Posted On Apr 19 2017 by

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …